Clinical Trials
22 trialsNCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07318051 2026-01-15
SCORE
Natera, Inc.
Recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT06645808 2025-12-29
VARTUTRACE
Var2 Pharmaceuticals
Phase EARLY_PHASE1 Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT03251378 2024-09-25
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
Phase 1 Completed
NCT06006390 2024-08-09
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT06126406 2023-11-13
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Novartis
Phase 1 Completed
NCT00101972 2022-02-22
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Phase 1 Completed
NCT00041652 2021-08-19
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
Gilead Sciences
Phase 1/2 Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT04088955 2020-03-11
ADOPTR
Proteus Digital Health, Inc.
Unknown
NCT02303353 2017-02-24
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
SPGO Research Mannheim GmbH
Unknown
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00988936 2012-08-22
K5-101
Siemens Molecular Imaging
Phase 2 Completed
NCT00028405 2005-06-24
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
Light Sciences LLC
Phase 1 Completed